BRIEF—Positive Phase IIa clinical study of UB-311 vaccine in Alzheimer's

Irish clinical-stage biotech firm United Neuroscience (UNS) today announced positive top-line results from its Phase IIa clinical study of UB-311, a novel synthetic peptide vaccine targeting beta amyloid (Aβ) in the treatment of Alzheimer's disease.

The top-line Phase IIa data met the primary aims of safety and immunogenicity with a 96% response rate.

All secondary endpoints - including Amyloid PET burden, CDR-SB, ADCS-ADL, ADAS-Cog and MMSE - pointed directionally in favor of UB-311, though not statistically significant with the study sample size.

"The positive results show that we can safely raise and maintain anti-Aβ antibody titers in a predictable and sustained manner," said Peter Powchik, executive vice president of R&D at UNS.

"High response rates, reproducibility of response and generation of antibodies directed to relevant toxic protein species are key elements of an effective therapeutic vaccine for neurodegenerative conditions. The UNS platform is proving that it can deliver on these requirements," he added.